Hansoh Acquires China Rights to Novel Synexis Antifungal

Hansoh Pharma of Jiangsu Province acquired China rights to a late-state anti-fungal candidate for difficult-to-treat and drug-resistant infections from Synexis, a New Jersey biotech. Hansoh will make a $10 million upfront payment to Synexis, plus unspecified milestones and royalties. Ibrexafungerp is a first-in-class, broad-spectrum triterpenoid antifungal agent with both IV and oral formulations. It is currently under US NDA review to treat vaginal yeast infections and in late-stage development for other indications including fungal infections in hospitalized patients. More details.... Stock Symbols: (HK: 3692) (NSDQ: SCYX) Share this with colleagues: // //